Mersana Therapeutics posted its best trading day ever, jumping 209% after Day One Biopharmaceuticals agreed to acquire the company for up to $285 million. The stock surged despite multiple analyst downgrades, with firms saying competing bids are unlikely. Retail traders called the deal a strong bargain for Day One and cited confidence in Mersana broader pipeline.